Do you know of any relationship with Lyme Disease and Tinnitus? Or Lyme Disease and hearing loss?
Lyme disease is caused by the bacteria Borrelia burgdorferi and is transmitted by the deer tick Ixodes ricinus. The incidence of Lyme disease in the United States has been increasing since first reported in 1977. The disease exhibits three stages with various associated symptoms. The hallmark of the first stage is a spreading rash called erythema migrans. During the second stage, cranial neuropathies have been observed. In the third stage, neurologic symptoms related to encephalopathy and demyelinating disease can be observed.
Among the otolaryngologic manifestations, facial weakness is the best appreciated and can sometimes be bilateral. Dizziness can occur in approximately 12% of patients. A sudden onset or rapidly progressive sensorineural hearing loss (typically bilateral) and/or tinnitus occur in a small percentage of patients ("T 5%). Among patients who have experienced a sudden sensorineural hearing loss, seropositivity to Borrelia is several times higher than within the general population. The hearing loss can frequently be low-frequency. Lyme disease is treated with antibiotic therapy, and highly variable response rates of hearing loss and tinnitus to treatment have been reported.
Lance E. Jackson, MD is an Otologist/Neurotologist and president of the Ear Institute of Texas in San Antonio, TX. Refer to his web sitewww.earsoftexas.comfor a list of publications and services provided.
The goal of this course is to introduce the attendee to the advanced science of clinical pharmacology that impacts the practice of the audiologist. The clinical use and understanding of the pharmacodynamics, pharmacokinetics, and the potential positive and negative outcomes of medications will be emphasized.
It has been estimated that up to 60% of hearing loss is genetic. In this presentation, we will discuss the most common forms of genetic deafness, appropriate referrals to genetics professionals and what patients can expect from a genetics evaluation.
This article discusses issues surrounding hearing preservation with cochlear implantation surgery. This discussion includes factors that may affect hearing preservation with traditional cochlear implant devices as well as a discussion of research findings with hybrid/EAS devices. Editor's note 10/7/11: There have been rapid changes in the field of cochlear implantation thanks to ongoing advances in research and technology. Just since this article has been published, there are some very recent developments in EAS research at the University of Iowa. In the last three months, they have been given FDA approval to conduct two feasibility trials to study preservation of hearing with Nucleus hybrid cochlear implants in those with severe hearing loss and will be implanting children between the ages of 5 and 15 years of age. This new information about the Iowa-sponsored feasibility trials contradicts two points within questions 15 to 18 of the article: Adults with greater hearing impairment than those in the clinical trial described in the article are eligible for implantation with a Nucleus Hybrid L24 implant through the Iowa-sponsored feasibility trial, and the S12 and L24 devices are available to children through the feasibility study at the University of Iowa. Please keep this is mind as you read the article. As new advances are made in this exciting area of research and practice, we will try our best to keep you informed!
This presentation will focus on a basic overview of acoustic neuromas. We will discuss causes, symptoms, risk factors, complications, testing and diagnosis, treatments/medical management, coping and support, prognosis, and case studies.